These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 8517694

  • 1. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.
    Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ.
    Antimicrob Agents Chemother; 1993 May; 37(5):1073-81. PubMed ID: 8517694
    [Abstract] [Full Text] [Related]

  • 2. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy.
    Highet VS, Forrest A, Ballow CH, Schentag JJ.
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():55-63. PubMed ID: 10225573
    [Abstract] [Full Text] [Related]

  • 3. Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime.
    Goss TF, Forrest A, Nix DE, Ballow CH, Birmingham MC, Cumbo TJ, Schentag JJ.
    Ann Pharmacother; 1994 Mar; 28(7-8):863-8. PubMed ID: 7949501
    [Abstract] [Full Text] [Related]

  • 4. Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches.
    Conil JM, Georges B, de Lussy A, Khachman D, Seguin T, Ruiz S, Cougot P, Fourcade O, Houin G, Saivin S.
    Int J Antimicrob Agents; 2008 Dec; 32(6):505-10. PubMed ID: 18768301
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.
    Schentag JJ.
    J Chemother; 1999 Dec; 11(6):426-39. PubMed ID: 10678784
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.
    Xu Y, Jin L, Liu N, Luo X, Dong D, Tang J, Wang Y, You Y, Liu Y, Chen M, Yu Z, Hao Y, Gu Q.
    Int J Infect Dis; 2019 May; 82():79-85. PubMed ID: 30878630
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.
    Tran JQ, Ballow CH, Forrest A, Hyatt JM, Sands MF, Peloquin CA, Schentag JJ.
    J Antimicrob Chemother; 2000 Mar; 45():9-17. PubMed ID: 10719007
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
    McKinnon PS, Paladino JA, Schentag JJ.
    Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H, Dalhoff A.
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.